InvestorsHub Logo
Post# of 175036
Next 10
Followers 745
Posts 15751
Boards Moderated 0
Alias Born 12/23/2010

Re: jfkspire post# 29864

Tuesday, 05/12/2015 2:30:43 PM

Tuesday, May 12, 2015 2:30:43 PM

Post# of 175036
...yes. And as a review here are some of the outstanding, if i may say, advantages ADMD's very own developed brachytherapy device using Y-90: has even over other current brachytherapy biotechs using Y-90(!)....let alone older type of cancer treatments offered by many a billion dollar Market Cap biotech being used right now which some may be outdated in this comparison ; Y-90 is a future oncology therapy that is just gathering steam these years....:




. Based upon its studies and analyses, or general application of experience with current brachytherapy devices and yttrium-90, the Company believes that if we are able to obtain regulatory approval and adequate financing to commercialize our products, our brachytherapy products are likely to offer the following benefits, among others, for patients and medical professionals:

·
Maximizing Therapeutic Index: The short-range beta particles emitted by Y-90 deliver radiation energy within a tight range. This enables radiation to be selectively delivered to target tissues while minimizing radiation dose to nearby normal tissues. High therapeutic indices imply that more radiation energy may be imparted to cancer tissues, with less radiation reaching adjacent normal tissues.

·
Half Life: The industry-standard products have a half-life of 17 days, meaning the patient is radioactive for over two months. The Company’s brachytherapy products use the yttrium-90 isotope, which has a half-life of just 2.7 days. A patient treated with Y-90 would be close to radiation free in 10 days.

·
Optimized Delivery Method: Current brachytherapy devices place permanent metal particles seeds in the prostate by using up to 30 large gauge needles. By contrast, the Company’s biodegradable polymer carrying Y-90 particles may be administered with small-gauge needles.

·
No Permanent Seeds Remaining: Current brachytherapy devices place permanent metal seeds in the tumor. The Company’s Y-90 RadioGel™ device utilizes a biodegradable, non-toxic polymer that is ultimately absorbed by the body. This eliminates the possibility of a long-term seed migration or other problems that may sometimes arise when seeds remain in the body.




...just got onto Twitter, its actually more fun then i thought it would be - give me a Tweet sometime-!


https://mobile.twitter.com/RealDiamondFire

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent RDGL News